Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03071081
Recruitment Status : Completed
First Posted : March 6, 2017
Last Update Posted : September 20, 2018
Sponsor:
Information provided by (Responsible Party):
Topivert Pharma Ltd

Brief Summary:
This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: TOP1288 Drug: Placebo to TOP1288 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 3 dose groups (2 arms per dose group)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers
Actual Study Start Date : February 8, 2017
Actual Primary Completion Date : June 2, 2017
Actual Study Completion Date : June 2, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TOP1288 200mg BID
1 day dosing
Drug: TOP1288
Oral TOP1288

Placebo Comparator: Placebo to TOP1288 200mg BID
1 day dosing
Drug: Placebo to TOP1288
Oral placebo to TOP1288

Experimental: TOP1288 1g BID
1 day dosing
Drug: TOP1288
Oral TOP1288

Placebo Comparator: Placebo to TOP1288 1g BID
1 day dosing
Drug: Placebo to TOP1288
Oral placebo to TOP1288

Experimental: TOP1288 Xg (where X is <=1g) BID
7 days dosing
Drug: TOP1288
Oral TOP1288

Placebo Comparator: Placebo to TOP1288 Xg
7 days dosing
Drug: Placebo to TOP1288
Oral placebo to TOP1288




Primary Outcome Measures :
  1. Safety (AEs) [ Time Frame: To 7 days after last dose ]
    As measured by adverse events

  2. Safety (ECGs) [ Time Frame: To 7 days after last dose ]
    As measured by ECGs

  3. Safety (vital signs) [ Time Frame: To 7 days after last dose ]
    As measured by vital signs

  4. Safety (clinical lab tests) [ Time Frame: To 7 days after last dose ]
    As measured by clinical laboratory tests


Secondary Outcome Measures :
  1. Pharmacokinetic profile Cmax [ Time Frame: 0-48 hours ]
    Observed maximum plasma concentration, taken directly from the individual concentration-time curve (Cmax)

  2. Pharmacokinetic profile AUC [ Time Frame: 0-48 hours ]
    Area under the plasma concentration-curve (AUC)

  3. Pharmacokinetic profile AUC0-12h [ Time Frame: 0-12 hours ]
    AUC from time zero to 12 h (AUC0-12h)

  4. Pharmacokinetic profile AUC0-24h [ Time Frame: 0-24 hours ]
    AUC from time zero to 24 h (AUC0-24h)

  5. Pharmacokinetic profile AUC0-t [ Time Frame: 0-48 hours ]
    AUC from time zero to the last measurable concentration (AUC0-t)

  6. Pharmacokinetic profile Racc [ Time Frame: 0-48 hours ]
    Accumulation ratio of the AUC (Racc) (multiple dose part only)

  7. Pharmacokinetic profile tmax [ Time Frame: 0-48 hours ]
    Time to reach maximum concentration, taken directly from the individual concentration-time curve (tmax)

  8. Pharmacokinetic profile t½ [ Time Frame: 0-48 hours ]
    Terminal half-life (t½)

  9. Pharmacokinetic profile λz [ Time Frame: 0-48 hours ]
    Terminal elimination rate constant (λz)

  10. Pharmacokinetic profile CL/F [ Time Frame: 0-48 hours ]
    Apparent total clearance from plasma after oral administration (CL/F)

  11. Pharmacokinetic profile Vz/F [ Time Frame: 0-48 hours ]
    Volume of distribution of the absorbed fraction (Vz/F)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is a healthy male, aged between 18 and 55 years of age (inclusive) at Screening.
  2. Subject has a body mass index (BMI) of between 18.0 and 29.9 kg/m2 (inclusive), with a body weight of at least 50 kg at Screening.
  3. Subject is in good physical and mental health in the opinion of the Investigator.
  4. Subject has clinical laboratory test results within the reference ranges of the testing laboratory unless results outside the reference ranges are deemed not clinically significant by the Investigator at Screening and Day -1.
  5. Subject has a supine blood pressure and pulse rate within the normal range after 5 minutes' rest (systolic blood pressure: 90 to 140 mmHg, diastolic blood pressure: 40 to 90 mmHg, pulse rate: 40 to 90 beats per minute) at Screening and Day -1.
  6. Subjects must be willing to comply with the contraception restrictions of the protocol for this study.
  7. Subject has regular bowel opening of usually 1 motion per day of normal consistency.

Exclusion Criteria:

  1. Subject has participated in another study of an investigational medication (or a medical device) within the last 3 months or 5 half-lives of the investigational medication, whichever is longer, prior to the first day or dosing.
  2. Subject has made a blood donation (> 400 mL) or had a comparable blood loss (> 350 mL) within the last 3 months prior to first administration of study drug.
  3. Subject tests positive for human immunodeficiency virus (HIV)-1/2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies at Screening.
  4. Subject has a history of alcohol and/or drug abuse.
  5. Subject has an alcohol consumption of more than 21 units of alcohol per week.
  6. Subject tests positive for alcohol and/or drugs (urine tests) at Screening or admission.
  7. Subject has received any prescription or non-prescription medications, including over-the-counter medications, nutraceuticals (e.g., St. John's Wort, ginseng, kava kava, Ginkgo biloba and melatonin), foods or beverages containing grapefruit and vitamin supplements within 14 days prior to admission (Day -1) or nutraceuticals containing caffeine- or xanthine-related substances within 72 hours prior to admission (Day -1). Foods or beverages containing Seville-type (sour) oranges, or poppy seeds are also excluded within this time period.
  8. The subject has a history of daily consumption of 5 or more cups of coffee or tea.
  9. Subject has a known hypersensitivity to any components of the study drug.
  10. Subject has any history of any clinically significant acute or chronic condition affecting the colon and/or rectum and/or anus, including haemorrhoids and irritable bowel syndrome, sufficient to cause symptoms and/or that in the judgement of the PI and the Sponsor's study Physician/Medical Monitor would interfere with the subject's participation in the study.
  11. Any findings on pre-dose endoscopy that in the PI's judgement would interfere with subject participation in the study.
  12. Subject has acute or chronic condition affecting GI motility such as constipation or diarrhoea that would, in the judgement of the PI and the Sponsor's study Physician/Medical Monitor, interfere with the subject's participation in the study
  13. Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischaemic heart disease, transient ischaemic attacks, stroke and peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status.
  14. Subject has an active infection (e.g., sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalisation or requiring parenteral antibiotic treatment) within 6 weeks prior to study drug administration.
  15. Subject has a history of positive tuberculosis test or evidence of possible tuberculosis or latent tuberculosis infection at Screening (interferon gamma release assay testing) that cannot be attributed to a prior Bacillus Calmette-Guérin inoculation.
  16. Subject has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
  17. Subject has any of the following haematology values at Screening or Day -1:

    • Haemoglobin, < 13 g/dL.
    • Absolute neutrophil count < 1.5 x 109/L (< 1500/μL).
  18. Subject has a 12-lead electrocardiogram (ECG) with results considered to be potentially clinically significant, e.g., QTcF > 450 ms, bundle branch block, evidence of myocardial ischaemia, at Screening or Day -1.
  19. Subject has an abnormality in the ECG that, in the opinion of the Investigator, increases the risks associated with participating in the study.
  20. Subject has renal or liver impairment at Screening or Day -1, defined as:

    • Serum creatinine level ≥ 135 μmol/L, or
    • Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2 x upper limit of normal, or
    • Alkaline phosphate and/or bilirubin > 1.5 x upper limit of normal (an isolated bilirubin 1.5 x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin is < 35%).
  21. Subject has active neoplastic disease or history of any neoplastic disease within 5 years of Screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care).
  22. Subject has any other acute or chronic illness which, in the opinion of the Investigator or Sponsor's study Physician/Medical Monitor, could pose a threat or harm to the subject's participation in the study.
  23. The subject has used nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 2 weeks prior to admission to the study centre (Day -1).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03071081


Locations
Layout table for location information
United Kingdom
PAREXEL Early Phase Clinical Unit
London, United Kingdom
Sponsors and Collaborators
Topivert Pharma Ltd
Investigators
Layout table for investigator information
Principal Investigator: Muna Albayaty, MBChB, FFPM Copenhagen Trial Unit, Center for Clinical Intervention Research
Layout table for additonal information
Responsible Party: Topivert Pharma Ltd
ClinicalTrials.gov Identifier: NCT03071081    
Other Study ID Numbers: TOP1288-TV-03
First Posted: March 6, 2017    Key Record Dates
Last Update Posted: September 20, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Colitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases